Imlygic(talimogene laherparepvec)
Imlygic (talimogene laherparepvec) is a gene pharmaceutical. Talimogene laherparepvec was first approved as Imlygic on 2015-10-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Imlygic
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imlygic | Biologic Licensing Application | 2025-04-04 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
talimogene laherparepvec, Imlygic, Amgen Inc. | |||
| 2122-10-27 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9325 | Injection, talimogene laherparepvec, per 1 million plaque forming units |
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 3 | 8 | 2 | — | 3 | 15 |
| Carcinoma | D002277 | — | C80.0 | 3 | 1 | 1 | — | — | 5 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 1 | 1 | — | — | 3 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | 1 | — | — | 2 |
| Squamous cell neoplasms | D018307 | — | — | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 1 | — | — | — | 4 |
| Sarcoma | D012509 | — | — | 2 | 4 | — | — | — | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 2 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | 1 | — | — | — | 2 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 2 | 1 | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
| Malignant pleural effusion | D016066 | — | J91.0 | 1 | 1 | — | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | 1 | 1 | — | — | — | 1 |
| Ductal carcinoma | D044584 | — | — | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Neurofibromatosis 1 | D009456 | — | Q85.01 | 1 | — | — | — | — | 1 |
| Neurofibromatoses | D017253 | — | Q85.00 | 1 | — | — | — | — | 1 |
| Neurofibroma | D009455 | EFO_0000622 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Herpes simplex | D006561 | — | B00 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Talimogene laherparepvec |
| INN | talimogene laherparepvec |
| Description | Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease (stages IIIb-IVM1a) and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%.
|
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1187560-31-1 |
| RxCUI | 1721264 |
| ChEMBL ID | CHEMBL2108727 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13896 |
| UNII ID | 07730V90L6 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,671 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,592 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use